

Announcement No. 5/2012

To NASDAQ OMX Copenhagen A/S

Exiqon A/S
Skelstedet 16
2950 Vedbæk
Denmark

Phone: +45 4566 0888
Fax: +45 4566 1888
exiqon@exiqon.com
www.exiqon.com
CVR/Tax Id: 18 98 44 31

29 March 2012

Exiqon A/S issues new warrants to the company's executive board

The supervisory board of Exiqon A/S has on this 29 March 2012 resolved to issue 2,268,849 warrants to the executive board of Exiqon A/S. All warrants have been issued in accordance with the authorization granted in article 3h of the articles of association.

The warrants issued entitle the warrant holders to subscribe for up to a nominal value of DKK 2,268,849 shares of DKK 1.00 each in Exiqon A/S, and the supervisory board has at the same time resolved to increase Exiqon A/S' share capital accordingly.

The exercise price for the issued warrants is DKK 12.90 per warrant, which corresponds to the average closing price of the Company's shares in the last five trading days up to and including 28 March 2012, plus 2.5% per year.

Issued warrants will vest for exercise by 1/3 over a period of three years to the effect that 1/3 of the warrants issued is exercisable as from the calendar day 12 months after issue, 1/3 on the calendar day 24 months after issue and 1/3 on the calendar day 36 months after grant.

Unexercised warrants lapse automatically immediately after the expiry of the first exercise period after 36 months from the exercise date of the relevant warrant.

The resolution of the supervisory board will be included in articles 3h1 and appendix 12 of the Company's articles of association.

Additional information

Lars Kongsbak, CEO, phone +45 4566 0888 (cell: +45 4090 2101)

Hans Henrik Chrois Christensen, CFO, phone +45 4566 0888 (cell: +45 4090 2131)

About Exiqon

Exiqon's products are based on the proprietary LNA™ technology. This technology offers unique advantages for detection of miRNA biomarkers for life science researchers, drug developers and cancer treating physicians working towards personalizing medicine. Exiqon operates in two business areas: Exiqon Life Sciences has established a position for itself as one of the market's leading providers of miRNA research products for miRNA analysis in cells. Our research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Life Sciences is also collaborating with pharmaceutical companies in their effort to develop new medicines based on miRNA as biological markers (Exiqon Pharma Services). Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions. Exiqon is listed on the NASDAQ OMX in Copenhagen. For more information about us, please visit www.exiqon.com.